A股異動丨紫光學大(000526.SZ)漲停 天津安特增持股份至20%
格隆匯2月13日丨紫光學大(000526.SZ)今日強勢漲停,現報30.18元,暫成交1.6億元,最新總市值29億元。

紫光學大12日晚間公告,天津安特在2019年12月18日至2020年2月11日期間,增持公司2.07%股權。增持後,天津安特與一致行動人椰林灣合計持有紫光學大20%股權。
值得注意的是,目前紫光系可以控制紫光學大23.76%的股份,仍為大股東。本次權益變動不會導致公司控股股東及實際控制人發生變化。如今金鑫通過天津安特持有紫光學大的20%的股份,在未來是否處置教育資產的問題上,雙方的話語權也將更加接近。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.